Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market: Strategic Insights Driving GLP-1 Receptor Agonist Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the GLP-1 Receptor Agonist Market Size By 2025?
In recent times, the GLP-1 receptor agonist market has seen consistent expansion. The market is anticipated to rise from $13.58 billion in 2024 to $14.09 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.8%. Factors contributing to this growth during the historical period include an increase in diabetes cases, clinical effectiveness, patient education and acceptance, worldwide health initiatives, and a patient preference for injection-based treatments.

How Big Is the GLP-1 Receptor Agonist Market Size Expected to Grow by 2029?
The market for GLP-1 receptor agonist is predicted to witness substantial expansion in the upcoming years, reaching approximately $17.36 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.4%. Factors contributing to this growth during the forecast period include an increased focus on managing lifestyles, advancements in personalized medicine, the broadening of indications, the emergence of next-generation products, and the integration with combination therapies. Key trends for the forecast period comprise the development of oral formulations, a renewed emphasis on combination therapies, strategic alliances and cooperative initiatives, changes in reimbursement policies and access, as well as a heightened focus on patient-centered methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

Which Key Market Drivers Powering GLP-1 Receptor Agonist Market Expansion and Growth?
The GLP-1 receptor agonist market is anticipated to surge due to the increasing prevalence of diabetes. Diabetes, a chronic disease, arises when there is either a deficiency in insulin production by the pancreas or an inability of the body to effectively use the insulin it produces. This leads to high blood sugar, a symptom of the metabolic disorder diabetes mellitus. GLP-1 receptor agonist is employed in the treatment of diabetes to encourage the body to make more insulin, thus reducing blood sugar levels. Consequently, the increase in diabetes cases would result in an upsurge in the market. To illustrate, in March 2024, the Office for Health Improvement and Disparities, a UK governmental department, reported that between March 2022 and March 2023, the proportion of type 1 diabetes patients receiving all eight suggested care procedures rose by 22%, while for type 2, it grew by 21%. Moreover, the percentage reaching target HbA1c levels climbed to 37.9%, the highest ever recorded by the National Diabetes Audit (NDA). Therefore, the escalating rate of diabetes is fueling the growth of the GLP-1 receptor agonist market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the GLP-1 Receptor Agonist Market?
The surge in product innovations in the GLP-1 receptor agonist market is a prominent trend gaining traction. Key players in this market are channeling their resources into the development of groundbreaking solutions to solidify their stature in the industry. For example, in May 2022, Eli Lilly and Company, a pharmaceutical firm based in the US committed to improving lives through their medical solutions, rolled out their FDA-endorsed product, Mounjaro. This product, a GIP and GLP-1 receptor agonist, is designed with a unique molecule that activates the body's receptors for the incretin hormones GIP and GLP-1. It is dispensed via a pen auto-injector which features a concealed, pre-fixed needle, eliminating the need for patients to touch or view it, and is available in 6 doses.

What Are the Emerging Segments in the GLP-1 Receptor Agonist Market?
The glp-1 receptor agonist market covered in this report is segmented -

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp

Who Are the Global Leaders in the GLP-1 Receptor Agonist Market?
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

Which are the Top Profitable Regional Markets for the GLP-1 Receptor Agonist Industry?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9631

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.